BrainsWay Ltd.'s SEC filings document foreign private issuer current reports for a medical technology company focused on noninvasive neurostimulation for mental health disorders. Recent Form 6-K reports furnish press releases and investor materials covering Deep TMS commercialization, FDA-cleared indications, payer reimbursement policies, clinical data, financial results, operating guidance, and strategic investments in provider networks and related neurostimulation assets.
The filings also identify the company as a Form 20-F filer and reference registration statements on Form S-8 and Form F-3. Exhibits disclose capital-allocation activity, customer and reimbursement developments, risk-factor themes in investor materials, and formal updates on the business model built around leasing and selling Deep TMS systems.
Brainsway Ltd. director Mitrany Rayten Michal Ety filed an initial statement of beneficial ownership. The filing shows 12,500 Ordinary Shares held directly, including 6,250 shares and 6,250 RSUs that vest quarterly until March 5, 2028. It also reports stock options over 27,500 shares granted on January 13, 2020 expiring in 2028 with a NIS 15.26 exercise price, and options over 25,000 shares granted on March 5, 2024 expiring in 2034 with a NIS 11.17 exercise price, with 12,500 of those options vesting quarterly until March 5, 2028. The Ordinary Shares may be represented by American Depositary Shares on a one-for-one basis.
Brainsway Ltd. director David Zacut filed an initial ownership report detailing his equity position in the company. He directly holds 1,382,865 Ordinary Shares as of the filing, including 1,370,365 shares held jointly with his spouse, 6,250 additional shares, and unvested RSUs for 6,250 shares that vest quarterly until March 5, 2028.
He also indirectly holds 363,545 Ordinary Shares through Meromei Elran David 2003 Ltd. and 45,058 Ordinary Shares through Meromei Elran Ltd., both wholly owned entities where he serves as sole director. In addition, he holds stock options over 25,000 Ordinary Shares, granted on March 5, 2024, with an exercise price of NIS 11.17 per share and an expiration date of March 5, 2034. The remaining options for 12,500 shares vest in equal quarterly installments until March 5, 2028. Each Ordinary Share may be represented by one American Depositary Share.
Brainsway Ltd. chief financial officer Ido Marom filed an initial ownership report showing his equity stake in the company. He directly holds 51,250 Ordinary Shares, a figure that includes unvested restricted stock units that will vest in scheduled quarterly installments through dates extending to March 2030.
Marom also holds stock options over 46,875 Ordinary Shares granted in August 2023 and 17,500 Ordinary Shares granted in March 2024, both vesting in equal quarterly installments through 2027 and 2028, with exercise prices of NIS 4.28 and NIS 11.17 per share, respectively. This filing records existing holdings rather than new market purchases or sales.
Brainsway Ltd. director Karen Sarid filed an initial ownership report showing equity in both shares and options. She holds 12,500 Ordinary Shares, a figure that includes 6,250 shares and 6,250 restricted stock units that vest quarterly until March 5, 2028. She also holds stock options over 25,000 Ordinary Shares, with the remaining 12,500 options vesting in equal quarterly installments through the same date and carrying an exercise price of NIS 11.17 per share. The Ordinary Shares may be represented by American Depositary Shares, each currently equal to one Ordinary Share.
Brainsway Ltd. director Lushi Avner reported initial equity holdings consisting of stock options and restricted stock units tied to the company’s ordinary shares. The filing shows stock options to purchase 12,500 ordinary shares, granted on March 5, 2024, with the remaining options vesting in equal quarterly installments until March 5, 2028 and expiring on March 5, 2034. The exercise price for these options is NIS 11.17 per share. In addition, Avner holds 6,250 unvested RSUs, each representing a contingent right to receive one ordinary share, vesting quarterly until March 5, 2028. The ordinary shares may be represented by American Depositary Shares, with each ADS currently corresponding to one ordinary share.
Brainsway Ltd. Chief Marketing Officer Naomi Rozenfeld filed an initial ownership report showing equity exposure through shares, RSUs and options. She holds 25,000 Ordinary Shares, including 25,000 unvested RSUs that begin vesting on March 10, 2027 and continue quarterly until March 10, 2030. She also holds stock options over 75,000 Ordinary Shares, granted on December 22, 2025, with 18,750 options vesting on December 22, 2026 and the rest vesting quarterly until December 22, 2029, at an exercise price of NIS 30.74 per share and expiring on December 22, 2035. The Ordinary Shares may also be represented by American Depositary Shares, each currently equal to one Ordinary Share.
Brainsway Ltd. filed a Form 3 showing the initial equity holdings of Chief Executive Officer Levy Hadar. The filing reports direct ownership of 123,050 Ordinary Shares, which includes 16,800 shares and unvested restricted stock units that convert into shares as they vest.
Hadar also holds stock options over 80,000 Ordinary Shares granted on February 9, 2023 with an exercise price of NIS 3.65 per share, vesting in equal quarterly installments until February 13, 2027. Additional options cover 62,500 Ordinary Shares granted on March 5, 2024 at an exercise price of NIS 11.17 per share, vesting in equal quarterly installments until March 5, 2028.
Brainsway Ltd. executive Dr. Yiftach Roth, the Chief Scientist, filed an initial statement of beneficial ownership showing he holds 1,079,305 Ordinary Shares. This figure includes shares held jointly with his spouse, additional individually held shares, and unvested restricted stock units that vest gradually through 2030.
Brainsway Ltd. VP of Medical Affairs Colleen Hanlon filed an initial Form 3 detailing her equity position in the company. She directly holds 53,881 Ordinary Shares, including 20,381 shares and multiple RSU grants that vest in quarterly installments through dates extending to March 10, 2030. She also holds stock options over 10,000 Ordinary Shares, granted on March 5, 2024, with an exercise price of NIS 11.17 per share and an expiration date of March 5, 2034, with 5,000 of these options scheduled to vest in equal quarterly installments until March 5, 2028.
Brainsway Ltd. director Jonathan K. Shulkin filed an initial ownership report showing only existing indirect holdings, with no new share purchases or sales. The filing lists Ordinary Shares, which are represented by American Depositary Shares on the market, each equal to one Ordinary Share.
Shulkin reports indirect ownership of 536,494 Ordinary Shares through Tikvah Partners LLC, and 5,314,950 Ordinary Shares through Valor Brainsway Holdings LLC